← Back to Screener
Fortress Biotech, Inc. (FBIO)
Price$2.32
Favorite Metrics
Price vs S&P 500 (26W)-24.03%
Price vs S&P 500 (4W)-30.29%
Market Capitalization$74.71M
P/E Ratio (Annual)10.96x
All Metrics
Book Value / Share (Quarterly)$1.59
P/TBV (Annual)5.10x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-5.82%
Cash Flow / Share (Quarterly)$-2.10
Price vs S&P 500 (YTD)-40.54%
Gross Margin (TTM)66.92%
Net Profit Margin (TTM)10.77%
EPS (TTM)$0.17
10-Day Avg Trading Volume0.46M
EPS Excl Extra (TTM)$0.17
Revenue Growth (5Y)6.77%
EPS (Annual)$0.24
Dividend / Share (Annual)$0.02
ROI (Annual)6.23%
Gross Margin (Annual)66.92%
Net Profit Margin (5Y Avg)-69.82%
Cash / Share (Quarterly)$2.53
P/E Basic Excl Extra (TTM)10.96x
Revenue Growth QoQ (YoY)6.34%
P/E Normalized (Annual)10.96x
ROA (Last FY)3.67%
Revenue Growth TTM (YoY)9.69%
EBITD / Share (TTM)$-0.72
ROE (5Y Avg)-144.95%
Operating Margin (TTM)-68.39%
Cash Flow / Share (Annual)$-2.10
P/B Ratio1.50x
P/B Ratio (Quarterly)2.28x
Net Income / Employee (Annual)$0
EV / Revenue (TTM)0.87x
Net Interest Coverage (TTM)-3.18x
ROA (TTM)3.87%
EPS Incl Extra (Annual)$0.24
Current Ratio (Annual)2.49x
Quick Ratio (Quarterly)2.20x
3-Month Avg Trading Volume0.86M
52-Week Price Return51.63%
P/E Incl Extra (TTM)10.96x
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$0.71
P/S Ratio (Annual)1.18x
Asset Turnover (Annual)0.34x
52-Week High$4.53
Operating Margin (5Y Avg)-194.96%
EPS Excl Extra (Annual)$0.24
CapEx CAGR (5Y)25.86%
Tangible BV CAGR (5Y)3.44%
26-Week Price Return-17.14%
Quick Ratio (Annual)2.20x
13-Week Price Return-33.33%
Total Debt / Equity (Annual)1.19x
Current Ratio (Quarterly)2.49x
Enterprise Value$54.831
Revenue / Share Growth (5Y)-24.91%
Asset Turnover (TTM)0.36x
Book Value / Share Growth (5Y)-36.92%
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)1.74x
Pretax Margin (Annual)-53.01%
Cash / Share (Annual)$2.53
3-Month Return Std Dev65.59%
Gross Margin (5Y Avg)62.38%
Net Income / Employee (TTM)$0
ROE (Last FY)13.66%
Net Interest Coverage (Annual)-3.20x
EPS Basic Excl Extra (Annual)$0.24
Receivables Turnover (TTM)3.16x
Total Debt / Equity (Quarterly)1.19x
EPS Incl Extra (TTM)$0.17
Receivables Turnover (Annual)3.16x
ROI (TTM)6.87%
Dividend Growth Rate (5Y)-54.94%
P/S Ratio (TTM)1.18x
Pretax Margin (5Y Avg)-192.91%
Revenue / Share (Annual)$2.27
Tangible BV / Share (Annual)$0.71
Forward P/E3.79x
Price vs S&P 500 (52W)17.00%
P/E Ratio (TTM)10.96x
Year-to-Date Return-36.61%
5-Day Price Return-4.13%
EPS Normalized (Annual)$0.24
ROA (5Y Avg)-22.03%
Net Profit Margin (Annual)10.77%
Month-to-Date Return-16.85%
Cash Flow / Share (TTM)$-25.80
EBITD / Share (Annual)$-0.76
Operating Margin (Annual)-68.12%
LT Debt / Equity (Annual)1.19x
ROI (5Y Avg)-44.39%
P/E Excl Extra (TTM)10.96x
LT Debt / Equity (Quarterly)1.19x
EPS Basic Excl Extra (TTM)$0.17
P/TBV (Quarterly)5.10x
Payout Ratio (Annual)9.74%
P/B Ratio (Annual)2.28x
Dividend / Share (TTM)$0.02
Inventory Turnover (TTM)1.74x
Pretax Margin (TTM)-53.28%
Book Value / Share (Annual)$1.59
Price vs S&P 500 (13W)-35.71%
Dividend Yield (TTM)0.89%
Beta1.19x
Revenue / Share (TTM)$2.08
ROE (TTM)15.86%
52-Week Low$1.45
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.13
4.13
4.13
4.13
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
FBIOFortress Biotech, Inc. | 1.18x | 9.69% | 66.92% | — | $2.32 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Fortress Biotech is a biopharmaceutical company focused on acquiring, developing, and commercializing dermatology and therapeutic products. Its portfolio includes key dermatology brands—Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm—which represent the majority of revenues. The company also operates in oncology and other therapeutic sectors through its subsidiaries.